The current dilemma of new drug research and development-the multi-dimensional use of big data and artificial intelligence

Shanghai October 15, 2021 /PRNewswire The era of hard technology represented is accelerating

At the opening ceremony, Academician Chen Kaixian introduced the development trend of biomedicine and the application of big data and artificial intelligence in the field of biomedicine

On the afternoon of October 13th, the sub-forum "Application of Data + Intelligence in New Drug Research and Development" hosted by Leadstar Biotech and Yudao Biotech was grandly held in Dongjiao Hotel

The forum was divided into two parts: "keynote speech" and "round table discussion"

As Ms.

Leadstar Bio is a one-stop solution for new drug research and development based on multi-dimensional real-world data insights for the R&D teams of domestic and foreign pharmaceutical and biotechnology companies, assisting the medical digital department to obtain drug clinical trials based on multi-dimensional real-world data insights An innovative company with strategic support and drug commercialization services

In the field of small nucleic acids, Ms.

Yudao Biosciences is a platform-based company that applies artificial intelligence and big data to drug development.

ALLOSTARTM, the foundation of this platform is the development of the allosteric database ALLOMATRIX.

Qingyun Ruijing Biology also plays a very important role in improving the efficiency of drug research and development

Qingyun Ruijing Biotech's MicroED technology directly reduces the resolvable crystal size by 500 times to 0.

In the roundtable discussion session, the host and guests had a lively discussion on the implementation of data and intelligence in the field of new drug research and development, mainly from the current pain points of FIC or source innovative new drug research and development; the support of data and intelligence in each stage of new drug research and development, and In the field of new drug research and development, the actual implementation of data and intelligent applications is carried out

On the issue of artificial intelligence and big data's support for the development of new drugs, the guests had a lively discussion

When talking about implementation and areas for improvement, the four guests agreed that the quality and credibility of the data need to be improved, because low-quality data not only affects the model itself, but also affects the accuracy of the result prediction

The audience at the conference also responded enthusiastically, and exchanged opinions with the forum guests from multiple angles such as the compliance of data and technology applications, and the application potential of new technologies such as blockchain

This forum allowed us to understand that pharmaceutical R&D is facing the dilemma of reduced R&D efficiency and rising R&D costs.

Although in China, the application of artificial intelligence and big data in the medical field is still in its infancy, there has not been a large number of research and development results
.
But we have reason to believe that as time accumulates, more and more companies such as Leadstar Bio and Yudao Bio will appear in China
.
Their brave attempts will definitely help China's pharmaceutical R&D to reach a higher level and to a broader world
.

Source: Leadstar Bio